drugset / Trial / NCT07108894
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
RandomizedParallel-groupTriple-blindTreatment
Summary
This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo
Timeline
- Start
- 2025-07-25
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABCL575 | Unknown | — | Subcutaneous |
Indications
No indication recorded.